Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | KLK8 | O60259 | 2/20 | 0.45 |
| ▸ | PLAU | P00749 | 2/20 | 0.45 |
| ▸ | KLK2 | P20151 | 2/20 | 0.45 |
| ▸ | KLK4 | Q9Y5K2 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ANPEP | P15144 | 1/20 | 0.42 |
| ▸ | LAP3 | P28838 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2991403 | 0.84 | SRC (0.50) | SRCL3MBTL1TDP1KLK8PLAU | |
| SCHEMBL9377254 | 0.82 | SRC (0.48) | SRCL3MBTL1TDP1KLK8PLAU | |
| SCHEMBL15475043 | 0.82 | GAA (0.55) | L3MBTL1MEN1KMT2A | |
| SCHEMBL8083309 | 0.82 | SRC (0.57) | SRCUSP2L3MBTL1TDP1ALOX15 | |
| SCHEMBL2720079 | 0.81 | POLB (0.59) | SRCL3MBTL1TDP1MEN1HTT | |
| SCHEMBL28916176 | 0.81 | SRC (0.47) | SRCL3MBTL1TDP1MEN1HTT | |
| SCHEMBL10878627 | 0.80 | SRC (0.50) | SRCL3MBTL1TDP1ALOX15KLK8 | |
| SCHEMBL2154812 | 0.80 | SMN1; SMN2 (0.49) | SRCL3MBTL1TDP1KLK8PLAU | |
| SCHEMBL4459747 | 0.78 | SRC (0.58) | SRCL3MBTL1TDP1KLK8PLAU | |
| SCHEMBL1450572 | 0.78 | LMNA (0.48) | SRCL3MBTL1MEN1KMT2ABTN3A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9951022-B2 | Method for producing 4,4,7-trifluoro-1,2,3,4-tetrahydro-5H-1-benzazepine compound and intermediate used in the method | TACURION (US) | 2018-04-24 | — | — | US | claimed |
| EP-2860175-B1 | METHOD FOR PRODUCING 4,4,7-TRIFLUORO-1,2,3,4-TETRAHYDRO-5H-1-BENZAZEPINE COMPOUND AND INTERMEDIATE FOR SYNTHESIS THEREOF | TACURION (US) | 2017-11-29 | — | — | EP | claimed |
| US-20170158639-A1 | METHOD FOR PRODUCING 4,4,7-TRIFLUORO-1,2,3,4-TATRAHYDRO-5H-1-BENZAZEPINE COMPOUND AND INTERMEDIATE USED IN THE METHOD | TACURION (US) | 2017-06-08 | — | — | US | claimed |
| US-9598373-B2 | Method for producing 4,4,7-trifluoro-1,2,3,4-tetrahydro-5H-1-benzazepine compound and intermediate used in the method | TACURION (US) | 2017-03-21 | — | — | US | claimed |
| EP-2698859-B1 | NON-AQUEOUS ELECTROLYTIC SOLUTION AND ELECTRICITY-STORAGE DEVICE USING THE SAME | UBE INDUSTRIES (JP) | 2016-07-27 | — | — | EP | claimed |
| US-20150141641-A1 | METHOD FOR PRODUCING 4,4,7-TRIFLUORO-1,2,3,4-TETRAHYDRO-5H-1-BENZAZEPINE COMPOUND AND INTERMEDIATE USED IN THE METHOD | ASTELLAS PHARMA INC. (JP) | 2015-05-21 | — | — | US | claimed |
| EP-2860175-A1 | METHOD FOR PRODUCING 4,4,7-TRIFLUORO-1,2,3,4-TETRAHYDRO-5H-1-BENZAZEPINE COMPOUND AND INTERMEDIATE FOR SYNTHESIS THEREOF | Astellas Pharma Inc. (JP) | 2015-04-15 | — | — | EP | claimed |
| CN-119823200-A | Preparation method of fondaparinux sodium heparin pentasaccharide and method for synthesizing fondaparinux sodium heparin pentasaccharide by taking naphthylmethyl as temporary protecting group | 海南大学 | 2025-04-15 | — | — | CN | disclosed |
| WO-2023057645-A1 | METHODS FOR THE PRODUCTION OF SORANGICINS AND THEIR ANALOGUES | OTTO-VON-GUERICKE-UNIVERSITÄT MAGDEBURG (DE) | 2023-04-13 | — | — | WO | disclosed |
| US-9951022-B2 | Method for producing 4,4,7-trifluoro-1,2,3,4-tetrahydro-5H-1-benzazepine compound and intermediate used in the method | TACURION (US) | 2018-04-24 | — | — | US | disclosed |
| US-9951022-B2 | Method for producing 4,4,7-trifluoro-1,2,3,4-tetrahydro-5H-1-benzazepine compound and intermediate used in the method | TACURION (US) | 2018-04-24 | — | — | US | disclosed |
| US-9951022-B2 | Method for producing 4,4,7-trifluoro-1,2,3,4-tetrahydro-5H-1-benzazepine compound and intermediate used in the method | TACURION (US) | 2018-04-24 | — | — | US | disclosed |
| EP-2860175-B1 | METHOD FOR PRODUCING 4,4,7-TRIFLUORO-1,2,3,4-TETRAHYDRO-5H-1-BENZAZEPINE COMPOUND AND INTERMEDIATE FOR SYNTHESIS THEREOF | TACURION (US) | 2017-11-29 | — | — | EP | disclosed |
| EP-1345603-A1 | (HALO-BENZO CARBONYL)HETEROCYCLO FUSED PHENYL P38 KINASE INHIBITING AGENTS | Merck & Co., Inc. (US) | 2003-09-24 | — | — | EP | disclosed |
| WO-2002058695-A9 | (HALO-BENZO CARBONYL)HETEROCYCLO FUSED PHENYL P38 KINASE INHIBITING AGENTS | MERCK & CO INC (US) | 2003-09-12 | — | — | WO | disclosed |
| EP-1326856-A1 | PYRIDINE DERIVATIVES WITH IKB-KINASE (IKK-BETA) INHIBITING ACTIVITY | Bayer Aktiengesellschaft (DE) | 2003-07-16 | — | — | EP | disclosed |
| US-20030092712-A1 | (Halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents | MERCK SHARP & DOHME CORP. | 2003-05-15 | — | — | US | disclosed |
| US-6562811-B1 | Inhibit I kappa B kinase beta (IKK- beta or IKK-beta) activity, thus inhibit nuclear factor kappa B (NF- kappa B) and can be used for the prophylaxis and treatment of inflammation | BAYER AKTIENGESELLSCHAFT (DE) | 2003-05-13 | — | — | US | disclosed |
| WO-2002058695-A1 | (HALO-BENZO CARBONYL)HETEROCYCLO FUSED PHENYL P38 KINASE INHIBITING AGENTS | MERCK & CO., INC. (US) | 2002-08-01 | — | — | WO | disclosed |
| WO-2002024679-A1 | PYRIDINE DERIVATIVES WITH IKB-KINASE (IKK-β) INHIBITING ACTIVITY | BAYER AKTIENGESELLSCHAFT (DE) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141641-A1 | METHOD FOR PRODUCING 4,4,7-TRIFLUORO-1,2,3,4-TETRAHYDRO-5H-1-BENZAZEPINE COMPOUND AND INTERMEDIATE USED IN THE METHOD | AVPR2, AVPR1A, AVPR1B | SRC 4858/4885USP2 3630/4885L3MBTL1 3423/4885 |
| US-20030092712-A1 | (Halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents | MAPK1, MAPK7, MAPKAPK2 | SRC 394/4885USP2 3492/4885L3MBTL1 3668/4885 |
| US-20170158639-A1 | METHOD FOR PRODUCING 4,4,7-TRIFLUORO-1,2,3,4-TATRAHYDRO-5H-1-BENZAZEPINE COMPOUND AND INTERMEDIATE USED IN THE METHOD | AVPR2, AVPR1A, AVPR1B | SRC 4840/4885USP2 2745/4885L3MBTL1 3516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.